Seems like a few healthcare stocks going on a move of late and the market finally waking up to how undervalued PIQ is compared to peers.
RHY - mkt cap ~$140m, large potential market but still a few years away (1-2 years?) from test hitting the mkt, no pipeline mentioned in AGM Preso.
RENX/RNLX - mkt cap ~A$700m, smaller target market than PIQ (going after late stage DKD), no commercial sales, no CE Mark, no pipeline mentioned in company presos.
PIQ - mkt cap $58m - large target market, test is CE Mark approved, initial licence deals executed, first sales in in CY21, broad/deep pipeline of other diagnostic tests.
Plus other mkt caps in peer group table below:
If PIQ has a market cap of $140m, like RHY, share price will be $1.33
If PIQ has a market cap of the ave of some of its peers below, say $250m, share price will be $2.38
I'll leave everyone to do their own calcs for what the SP would be if they get to RENX's mkt cap....
(20min delay)